The UV research groups (GIUV) are regulated in the 1st chapter of the Regulation ACGUV48/2013, which explains the procedure for creating new research structures. They are basic research and organizational structures that result from the voluntary association of researchers that share objectives, facilities, resources and common lines of research. These researchers are also committed to the consolidation and stability of their activity, work in groups and the capability to achieve a sustainable funding.

The research groups included in the previously mentioned Regulation are registered in the Register of Research Structures of the Universitat de València (REIUV), managed by the Office of the Vice-principal for Research. The basic information of these organisms can be found in this website.

Participants

Data related to research groups featured in various information dissemination channels shall not, under any circumstances, imply a statement or commitment regarding the employment or academic affiliation of individuals associated with the Universitat de València. Their inclusion is solely the responsibility of the group directors. Updates will be made upon request from interested parties.

  • Registered groups in the Register of Research Structures of the Universitat de València - (REIUV)

Stereoselective synthesis of analogues of bioactive natural products - SEAPNB

Reference of the Group:

GIUV2013-114

 
Description of research activity:
The fundamental objective of the group is to produce new types of molecules with pharmacological activity and whose structure is based on that of known natural products, which are also bioactive. Of the many types of pharmacological activities described, the group's main focus is on cytotoxic, anti-angiogenic and telomerase inhibitory activities, because of the strong influence these activities exhibit on cell proliferation processes. This gives them potential interest in anti-cancer therapeutics. Another type of pharmacological action that will also be investigated is antimalarial activity. The group was formed some years ago on the general line of synthesis of bioactive natural products. One of its members has been collaborating for years with another group at the Universitat Jaume I in Castellón, with which it has joint research projects. At the same time, the group collaborates with external groups to carry out and determine the biological activities of the aforementioned types. One of these groups, led by Doctors Isabel Fernández and Fernando Díaz, carries out its scientific activity in Madrid at the Centro de Investigaciones Biológicas (CIB), an entity included within the...The fundamental objective of the group is to produce new types of molecules with pharmacological activity and whose structure is based on that of known natural products, which are also bioactive. Of the many types of pharmacological activities described, the group's main focus is on cytotoxic, anti-angiogenic and telomerase inhibitory activities, because of the strong influence these activities exhibit on cell proliferation processes. This gives them potential interest in anti-cancer therapeutics. Another type of pharmacological action that will also be investigated is antimalarial activity. The group was formed some years ago on the general line of synthesis of bioactive natural products. One of its members has been collaborating for years with another group at the Universitat Jaume I in Castellón, with which it has joint research projects. At the same time, the group collaborates with external groups to carry out and determine the biological activities of the aforementioned types. One of these groups, led by Doctors Isabel Fernández and Fernando Díaz, carries out its scientific activity in Madrid at the Centro de Investigaciones Biológicas (CIB), an entity included within the CSIC. The topics currently being addressed concern the stereoselective synthesis and biological evaluation of non-natural analogues of two bioactive natural products, combretastatin A4 and colchicine. Both show a strong inhibitory effect on cell proliferation, which makes them products of application in anticancer therapy. The aim is to create non-natural analogues of these compounds with improved pharmacological properties. The other group is a unit within the multinational pharmaceutical company GlaxoSmithKlyne and is involved in malaria research. Our group has signed an agreement with this company that allows for the evaluation, both in vitro and in vivo, of the antimalarial properties of synthesised compounds. This is of particular importance as the evaluation of bioactive products on live animals is particularly costly and not normally possible in academic facilities.
[Read more][Hide]
 
Web:

http://www.uv.es/marcoj/

 
Scientific-technical goals:
  • Sintesis de analogos de compuestos biologicamente activos. Evaluacion de las propiedades antiangiogenicas, antimitoticas e inhibidoras de telomerasa
 
Research lines:
  • Stereoselective synthesis of analogues of bioactive natural products.The group's aim is to manufacture new molecules with pharmacological activity and a structure based on that of bioactive natural products. We are mainly concerned with cytotoxic, anti-angiogenic and telomerase inhibition activity, which are of interest in anticancer therapeutics.
 
Group members:
Name Nature of participation Entity Description
JUAN ALBERTO MARCO VENTURADirectorUniversitat de València - Estudi GeneralUVEG honorary professor
Research team
JUAN FRANCISCO SANZ CERVERAMemberUniversitat de València
ANA CARMEN CUÑAT ROMEROMemberUniversitat de València
FERNANDO DIAZ PEREIRACollaboratorConsejo Superior de Investigaciones Científicasresearcher
 
CNAE:
  • -
 
Associated structure:
  • Organic Chemistry
 
Keywords:
  • citotoxicidad, acción antitumoral, terapéutica anticáncer, angiogenesis, telomerasa, combretastatinas, colquicina